ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
1. 9ÔÂ5ÈÕ£¬ÉñÖÝϸ°ûͨ¸æ£¬¿ËÈÕ¹«Ë¾ÊÕµ½¹ú¼ÒÒ©¼à¾ÖÅú׼ǩ·¢µÄ¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·£¬Ô޳ɹ«Ë¾×ÔÖ÷Ñз¢µÄÖØ×é´ø×´ðåÕîÒßÃç²úÆ·SCTV04C×¢ÉäÒºÔÚ¿µ½¡³ÉÈËÖпªÕ¹Ô¤·ÀË®¶»¡ª´ø×´ðåÕ¶¾£¨Varicella Zoster Virus£¨VZV£©£©Ñ¬È¾ÒýÆðµÄ´ø×´ðåÕî¼°²¢·¢Ö¢µÄÁÙ´²ÊÔÑé¡£
2. 9ÔÂ5ÈÕ£¬º²Ë¼°¬Ì©Ðû²¼Ê׸öHX009ÁªºÏÖÎÁÆ2ÆÚÁÙ´²ÊÔÑé»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊ飬ÔÞ±¾Ç®Æ·¿ªÕ¹ÁªºÏÖÎÁÆÓÃÓÚµ¨µÀ¶ñÐÔÖ×Áö(BTC)µÄ2ÆÚÁÙ´²ÊÔÑé¡£HX009ÊǺ²Ë¼°¬Ì©×ÔÁ¦¿ª·¢µÄÒ»¿îÁÙ´²½×¶ÎµÄ¿¹PD-1ºÍCD47Ë«¹¦Ð§´ó·Ö×Ó°©Ö¢ÃâÒßÖÎÁƵÄÑо¿ÐÔÐÂÒ©¡£
3. 9ÔÂ5ÈÕ£¬¿µÔµÒ©Òµ£¨600557£©Ðû²¼Í¨¸æ³Æ£¬¹«Ë¾¿ËÈÕÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÇ©·¢µÄKYS202004A×¢ÉäÒº¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·¡£KYS202004A×¢ÉäÒºÊǹ«Ë¾×ÔÖ÷Ñз¢µÄÒ»ÖÖË«°ÐµãFcÈÚºÏÂѰף¬ÆäÄâÓÃË³Ó¦Ö¢ÎªÒøÐ¼²¡£¨Ò»ÖÖÒÅ´«ÓëÇéÐÎÅäÏàÖúÓÃÓÕ·¢µÄÃâÒ߽鵼µÄÂýÐÔ¡¢¸´·¢ÐÔ¡¢Ñ×Ö¢ÐÔ¡¢ÏµÍ³ÐÔ¼²²¡¡£ÁÙ´²ÌåÏÖΪÁÛмÐÔºì°ß»ò°ß¿é£¬¾ÖÏÞ»òÆÕ±éÂþÑÜ£©¡£
4. 9ÔÂ5ÈÕ£¬±±Â½Ò©ÒµÍ¨¸æ£¬¿ËÈտعÉ×Ó¹«Ë¾Õ㽺£²ýÒ©Òµ¹É·ÝÓÐÏÞ¹«Ë¾ÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÅú׼ǩ·¢µÄµâ¿Ëɳ´¼¡¶»¯Ñ§ÖÊÁÏÒ©ÉÏÊÐÉêÇëÅú׼֪ͨÊé¡·¡£µâ¿Ëɳ´¼£¨Iodixanol£©Îª±ÈÕÕ¼Áµâ¿Ëɳ´¼×¢ÉäÒºµÄÖÊÁÏÒ©£¬ÊÊÓÃÓÚ×¶¹ÜÄÚÔìÓ°¡¢ÐÄÄÔѪ¹ÜÔìÓ°¡¢¾²ÂöÄÚÄò·ÔìÓ°£¬Æä×÷ÓÃÔÀíÊÇÁ¬ÏµµâÔÚѪ¹Ü»ò×éÖ¯ÄÚÎüÊÕXÉäÏßÔì³ÉÓ°ÏñÏÔʾ¡£
1. 9ÔÂ4ÈÕ£¬Åµ»ªÐû²¼ÎªÁËÖª×ã¶ÔÖÎÁư©Ö¢µÄ·ÅÉäÐÔÒ©ÎïÁÆ·¨ÈÕÒæÔöÌíµÄÐèÇ󣬹«Ë¾ÕýÔÚÀ©½¨Éý¼¶Î»ÓÚÃÀ¹úÓ¡µÚ°²Äɲ¨Àû˹µÄÉú²ú»ùµØ£¬²¢ÍýÏëÔÚ¼ÓÀû¸£ÄáÑÇÖݽ¨Éèй¤³§¡£¾ÝϤ£¬Åµ»ª´Ë´Î¹²Í¶×ÊÁË2ÒÚ¶àÃÀÔªÓÃÓÚ½¨³§£¬Ð¹¤³§µÄ×ÊÖʺÍî¿ÏµÉóÅúÔ¤¼Æ½«ÓÚ2026ÄêÍê³É¡£
1. ¸ç±¾¹þ¸ù´óѧ¿µ½¡Óëҽѧ¿ÆÑ§Ñ§ÔºÃâÒßѧºÍ΢ÉúÎïѧϵת»¯Ò½Ñ§ºÍ¼ÄÉú³æÑ§ÖÐÐĵÄElena Ethel Vidal-CalvoÍŶÓNature Communications½ÒÏþÌâΪ¡°Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate¡±µÄÑо¿ÂÛÎÄ¡£ÕâÏîÑо¿Àֳɿª·¢ÁËÈýÖÖ¿¹Ì寬¶Ï£¬ËüÃÇÄÜÌØÒìÐÔµØÊ¶±ðÁ½ÖÖÆæÒìµÄÖ×ÁöÌ¥¶ùÈí¹ÇÁòËᣨofCS£©±íλ¡£Ê¹ÓÃÕâЩ¿¹Ì寬¶Ï¿ª·¢µÄ¿¹ÌåÒ©ÎïżÁªÎADC£©ºÍË«ÌØÒìÐÔÃâÒßϸ°ûÖ¸µ¼·Ö×Ó£¬¿ÉÒÔÓÐÓõØ×è¶ÏÁËÈËÀàºÍСÊó°©Ö¢µÄÖ×ÁöÉú³¤¡£ÕâЩ·¢Ã÷Ϊ¿ª·¢Õë¶Ô¶àÖÖÈËÀà¶ñÐÔÖ×ÁöµÄÆÕ±éÓÐÓõÄÖÎÁƼ°Õï¶ÏÊÖ¶ÎÌṩÁËÐÂÏ£Íû¡£
[1]Vidal-Calvo, E.E., Martin-Salazar, A., Choudhary, S. et al. Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate. Nat Commun 15, 7553 (2024). https://doi.org/10.1038/s41467-024-51781-0